fam yklovyr | Famvir tablets 500 mg, 3 pcs.
Special Price
$45.08
Regular Price
$53.00
In stock
SKU
BID463964
Latin name
FAMVIR
FAMVIR
Latin name
FAMVIR
Release form
White coated tablets, round, biconvex, with beveled edges.
Packaging
In the package 3 pcs.
Pharmacological action of
Famvir - an antiviral drug. After ingestion, famciclovir quickly turns into penciclovir, which is active against human herpes viruses, including Varicella zoster virus (herpes zoster virus) and Herpes simplex types 1 and 2 (herpes simplex and genital virus), as well as Epstein-Barr virus and cytomegalovirus.
Penciclovir enters the virus-infected cells, where, under the influence of viral thymidine kinase, it quickly turns into monophosphate, which, in turn, with the participation of cellular enzymes passes into triphosphate. Penciclovir triphosphate is present in virus-infected cells for more than 12 hours, inhibiting viral DNA replication in them.
The concentration of penciclovir triphosphate in uninfected cells does not exceed the minimum determined, therefore, at therapeutic concentrations, penciclovir does not affect uninfected cells.
Penciclovir is active against recently discovered acyclovir-resistant strains of Herpes simplex virus with altered DNA polymerase.
The incidence of resistance to famciclovir (penciclovir) does not exceed 0.3%, in patients with impaired immunity - 0.19%.
Resistance was detected at the beginning of treatment and did not develop during treatment or after the end of therapy. It was shown that famciclovir significantly reduces the severity and duration of postherpetic neuralgia in patients with herpes zoster.
It was shown that in patients with immunity due to HIV infection, famciclovir at a dose of 500 mg 2 times / day reduces the number of days of isolation of the herpes simplex virus (both with clinical manifestations and without them).
Indications
- Infections caused by the Varicella zoster virus (herpes zoster), including ophthalmic herpes and postherpetic neuralgia.
- Herpes simplex virus infections (types 1 and 2): primary infection, exacerbation of chronic infection, suppression of recurrent infection (for the prevention of exacerbations).
- Infections, caused by Varicella zoster and Herpes simplex viruses (type 1 and 2) in patients with reduced immunity.
Contraindications
- Hypersensitivity to famciclovir or any of the components of the drug.
- Hypersensitivity to penciclovir.
Use in pregnancy and lactation
Since the safety of Famvir in pregnant and lactating women has not been studied, its use in pregnancy and lactation is not recommended, unless the possible treatment benefits do not exceed the potential risk. It is not known whether penciclovir with breast milk is excreted in humans. Famciclovir does not have a pronounced effect on the spermogram, morphology, or motility of human sperm. In experimental studies, no embryotoxic and teratogenic effects of famciclovir and penciclovir were detected. Studies in rats administered famciclovir orally showed that penciclovir is excreted in breast milk. A decrease in fertility was noted in an experimental model in male rats, treated with famciclovir at a dose of 500 mg / kg body weight, in female rats a marked decrease in fertility was not observed.
Composition
1 tablet contains: famciclovir 500 mg.
Excipients: hydroxypropyl cellulose, anhydrous lactose, sodium starch glycolate, magnesium stearate.
Shell composition: hypromellose, titanium dioxide, polyethylene glycol 4000 (macrogol), polyethylene glycol 6000 (macrogol).
Dosage and administration of
Inside, for adults with acute herpetic infection - 250 mg 3 times a day for 7 days. With shingles (Varicella zoster) and high risk of developing postherpetic neuralgia - 250 mg 3 times a day for 7 days. Treatment should begin immediately after diagnosis. With genital herpes, caused by Herpes simplex (type II): for primary infection - 250 mg 3 times a day for 5 days, for relapses of chronic infection - 125 mg 2 times a day for 5 days. Treatment should begin immediately after the onset of the first symptoms of the disease. For prevention - 250 mg 2 times a day. Periodic discontinuation of the drug at intervals of 6-12 months is recommended to assess possible changes in the course of the disease. In patients with impaired renal excretory function, dose adjustment is required: with CC 30-59 ml / min - 250 mg 2 times a day with CC less than 30 ml / min - 125 mg 3 times a day. For patients on hemodialysis, 250 mg (for patients with Varicella zoster) and 125 mg (for patients with genital herpes), the dose should be taken immediately after the procedure, because after 4 hours of hemodialysis, the concentration of penciclovir in the plasma is reduced by approximately 75%.
Side effects of
In clinical studies, Famvir has good tolerance, including in patients with reduced immunity. Cases of headache and nausea were reported, however, these phenomena were mild or moderate and were observed with the same frequency in patients receiving placebo.
The following are adverse reactions and their frequency of occurrence based on data on spontaneous reports, as well as cases described in the literature, for the entire period during which Famvir is used in clinical practice. Adverse events reported during clinical trials in patients with reduced immunity coincided with those observed in patients with normal immunity.
The following criteria were used to assess the incidence of adverse reactions: very often (> 1/10) often (from> 1/100, <1/10) sometimes (> 1/1000, 1/10000, <1/1000) very rarely (<1/10000), including individual messages.
From the hemopoietic system: very rarely - thrombocytopenia.
From the side of the central nervous system: rarely - headache, confusion (mainly in elderly patients) is very rare - dizziness, drowsiness (mainly in elderly patients), hallucinations.
From the digestive system: rarely - nausea very rarely - vomiting, jaundice.
Dermatological reactions: very rarely - rash, itching, severe skin reactions.
Allergic reactions: very rarely - urticaria, severe skin reactions (including erythema multiforme).
overdose The reported cases of overdose (10.5 g) of Famvir were not accompanied by clinical manifestations.
Treatment: carrying out symptomatic and supportive therapy. Failure to follow the recommendations to reduce the dose of famciclovir, taking into account renal function in patients with kidney disease, noted cases of acute renal failure. Penciclovir is excreted in hemodialysis. Penziclovir plasma concentrations are reduced by 75% after hemodialysis for 4.
active substance
Famciclovir
Terms leave through pharmacies
In retseptu
lekarstvennaja tablet form
Indications
Genital Herpes, Herpes Zoster, Varicella, Herpes
Possible product names
FAMVIR 0.5 N3 TABLE P / O
Famvir 500mg Tab. PO X3
FAMVIR 500MG. No. 3 TAB. P / O
Famvir tab p / o 500mg N3
Famvir tab p / o 500mg x 3
Novartis Farma Stein AG, Switzerland
FAMVIR
Release form
White coated tablets, round, biconvex, with beveled edges.
Packaging
In the package 3 pcs.
Pharmacological action of
Famvir - an antiviral drug. After ingestion, famciclovir quickly turns into penciclovir, which is active against human herpes viruses, including Varicella zoster virus (herpes zoster virus) and Herpes simplex types 1 and 2 (herpes simplex and genital virus), as well as Epstein-Barr virus and cytomegalovirus.
Penciclovir enters the virus-infected cells, where, under the influence of viral thymidine kinase, it quickly turns into monophosphate, which, in turn, with the participation of cellular enzymes passes into triphosphate. Penciclovir triphosphate is present in virus-infected cells for more than 12 hours, inhibiting viral DNA replication in them.
The concentration of penciclovir triphosphate in uninfected cells does not exceed the minimum determined, therefore, at therapeutic concentrations, penciclovir does not affect uninfected cells.
Penciclovir is active against recently discovered acyclovir-resistant strains of Herpes simplex virus with altered DNA polymerase.
The incidence of resistance to famciclovir (penciclovir) does not exceed 0.3%, in patients with impaired immunity - 0.19%.
Resistance was detected at the beginning of treatment and did not develop during treatment or after the end of therapy. It was shown that famciclovir significantly reduces the severity and duration of postherpetic neuralgia in patients with herpes zoster.
It was shown that in patients with immunity due to HIV infection, famciclovir at a dose of 500 mg 2 times / day reduces the number of days of isolation of the herpes simplex virus (both with clinical manifestations and without them).
Indications
- Infections caused by the Varicella zoster virus (herpes zoster), including ophthalmic herpes and postherpetic neuralgia.
- Herpes simplex virus infections (types 1 and 2): primary infection, exacerbation of chronic infection, suppression of recurrent infection (for the prevention of exacerbations).
- Infections, caused by Varicella zoster and Herpes simplex viruses (type 1 and 2) in patients with reduced immunity.
Contraindications
- Hypersensitivity to famciclovir or any of the components of the drug.
- Hypersensitivity to penciclovir.
Use in pregnancy and lactation
Since the safety of Famvir in pregnant and lactating women has not been studied, its use in pregnancy and lactation is not recommended, unless the possible treatment benefits do not exceed the potential risk. It is not known whether penciclovir with breast milk is excreted in humans. Famciclovir does not have a pronounced effect on the spermogram, morphology, or motility of human sperm. In experimental studies, no embryotoxic and teratogenic effects of famciclovir and penciclovir were detected. Studies in rats administered famciclovir orally showed that penciclovir is excreted in breast milk. A decrease in fertility was noted in an experimental model in male rats, treated with famciclovir at a dose of 500 mg / kg body weight, in female rats a marked decrease in fertility was not observed.
Composition
1 tablet contains: famciclovir 500 mg.
Excipients: hydroxypropyl cellulose, anhydrous lactose, sodium starch glycolate, magnesium stearate.
Shell composition: hypromellose, titanium dioxide, polyethylene glycol 4000 (macrogol), polyethylene glycol 6000 (macrogol).
Dosage and administration of
Inside, for adults with acute herpetic infection - 250 mg 3 times a day for 7 days. With shingles (Varicella zoster) and high risk of developing postherpetic neuralgia - 250 mg 3 times a day for 7 days. Treatment should begin immediately after diagnosis. With genital herpes, caused by Herpes simplex (type II): for primary infection - 250 mg 3 times a day for 5 days, for relapses of chronic infection - 125 mg 2 times a day for 5 days. Treatment should begin immediately after the onset of the first symptoms of the disease. For prevention - 250 mg 2 times a day. Periodic discontinuation of the drug at intervals of 6-12 months is recommended to assess possible changes in the course of the disease. In patients with impaired renal excretory function, dose adjustment is required: with CC 30-59 ml / min - 250 mg 2 times a day with CC less than 30 ml / min - 125 mg 3 times a day. For patients on hemodialysis, 250 mg (for patients with Varicella zoster) and 125 mg (for patients with genital herpes), the dose should be taken immediately after the procedure, because after 4 hours of hemodialysis, the concentration of penciclovir in the plasma is reduced by approximately 75%.
Side effects of
In clinical studies, Famvir has good tolerance, including in patients with reduced immunity. Cases of headache and nausea were reported, however, these phenomena were mild or moderate and were observed with the same frequency in patients receiving placebo.
The following are adverse reactions and their frequency of occurrence based on data on spontaneous reports, as well as cases described in the literature, for the entire period during which Famvir is used in clinical practice. Adverse events reported during clinical trials in patients with reduced immunity coincided with those observed in patients with normal immunity.
The following criteria were used to assess the incidence of adverse reactions: very often (> 1/10) often (from> 1/100, <1/10) sometimes (> 1/1000, 1/10000, <1/1000) very rarely (<1/10000), including individual messages.
From the hemopoietic system: very rarely - thrombocytopenia.
From the side of the central nervous system: rarely - headache, confusion (mainly in elderly patients) is very rare - dizziness, drowsiness (mainly in elderly patients), hallucinations.
From the digestive system: rarely - nausea very rarely - vomiting, jaundice.
Dermatological reactions: very rarely - rash, itching, severe skin reactions.
Allergic reactions: very rarely - urticaria, severe skin reactions (including erythema multiforme).
overdose The reported cases of overdose (10.5 g) of Famvir were not accompanied by clinical manifestations.
Treatment: carrying out symptomatic and supportive therapy. Failure to follow the recommendations to reduce the dose of famciclovir, taking into account renal function in patients with kidney disease, noted cases of acute renal failure. Penciclovir is excreted in hemodialysis. Penziclovir plasma concentrations are reduced by 75% after hemodialysis for 4.
active substance
Famciclovir
Terms leave through pharmacies
In retseptu
lekarstvennaja tablet form
Indications
Genital Herpes, Herpes Zoster, Varicella, Herpes
Possible product names
FAMVIR 0.5 N3 TABLE P / O
Famvir 500mg Tab. PO X3
FAMVIR 500MG. No. 3 TAB. P / O
Famvir tab p / o 500mg N3
Famvir tab p / o 500mg x 3
Novartis Farma Stein AG, Switzerland
Write Your Own Review